Pharming Group (NASDAQ:PHAR) Stock Rating Reaffirmed by HC Wainwright

Pharming Group (NASDAQ:PHAR)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Thursday, Benzinga reports. They presently have a $37.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 335.80% from the company’s current price.

Pharming Group Trading Up 5.7 %

Shares of Pharming Group stock opened at $8.49 on Thursday. The company has a quick ratio of 2.65, a current ratio of 3.39 and a debt-to-equity ratio of 0.40. The firm has a market cap of $571.76 million, a price-to-earnings ratio of -53.06 and a beta of 0.14. Pharming Group has a twelve month low of $6.65 and a twelve month high of $13.40. The business has a 50-day moving average price of $7.79 and a 200-day moving average price of $8.89.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.01) earnings per share (EPS) for the quarter. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. The firm had revenue of $74.09 million for the quarter, compared to analysts’ expectations of $71.95 million. During the same period last year, the company earned $0.02 earnings per share. Equities research analysts anticipate that Pharming Group will post -0.15 EPS for the current fiscal year.

Institutional Trading of Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its stake in shares of Pharming Group (NASDAQ:PHAR) by 32.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 23,435 shares of the company’s stock after acquiring an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 as of its most recent SEC filing. 0.03% of the stock is currently owned by institutional investors and hedge funds.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.